Today's Endpoints News Lead Article Regarding Eli Lilly Actions and Plans, page-26

brryh, it is sure a problem when ATH has some 800 molecules to be tested and there are so many possible diseases in which these potential drugs may work. For that purpose, ATH has developed a "platform technology" ( see "Candidate product discovery and translational Biology Programs" in the annual report). They have also developed " Structure Activity Relationships (“SAR”) within chemical moieties that guide our chemists towards the design of novel therapeutics".
ATH also tells that "Our chemistry program is undertaken within laboratories leased from The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute, which is a multidisciplinary research center that specializes in medical, agricultural and environmental biotechnology.
Accommodating more than 500 research scientists, students and industry participants, the Bio21 Institute is one of the largest biotechnology research centers in Australia".
IMO, one needs to be an insider of these development systems to compare if the present system in ATH is better or worse than that of Lilly / Lycia system.